BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS and PI3Kα malignancies, has announced a definitive business combination agreement…
Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion Predictmedix AI Expands into US Market with Launch of Advanced AI Health Stations Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) (“Predictmedix” or the “Company”), a pioneering provider…
SINOVAC Announces New Board Following Privy Council Judgment and Outlines Next Steps Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, has announced significant developments following a ruling from the Privy Council. On February 8,…
Genethon Advances Gene Therapy Innovations on Rare Disease Day 2025 Genethon, a pioneering gene therapy research organization founded by the AFM-Telethon, marks Rare Disease Day by showcasing groundbreaking technological advancements that promise to usher in the next generation of gene…
Glaukos Receives FDA Acceptance for Epioxa™ NDA Submission Glaukos Corporation (NYSE: GKOS), a leading ophthalmic pharmaceutical and medical technology company specializing in innovative therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, has announced a significant regulatory milestone.…
Synnovation Therapeutics Doses First Patient in Phase I Trial for PI3Kα Inhibitor SNV4818 Synnovation Therapeutics Initiates Phase I Trial for SNV4818: A Potential Best-in-Class Pan-Mutant-Selective PI3Kα Inhibitor Introduction Synnovation Therapeutics, a precision medicine company dedicated to the discovery and development…
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company dedicated to developing novel therapies aimed at rebalancing inflammation to optimize health, announced today that the Nasdaq Stock Market LLC (“Nasdaq”) has formally notified the Company…
Lantern Pharma Publishes PCT Patent for AI Model Predicting BBB Permeability Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI) company dedicated to advancing cancer therapies and transforming the efficiency and timeline of oncology drug discovery and development, has…
Ventus Therapeutics Names Dr. Mona Kotecha as Chief Medical Officer Ventus Therapeutics, a clinical-stage biopharmaceutical company, has announced the appointment of Mona Kotecha, M.D., as its new Chief Medical Officer (CMO). Ventus is advancing two novel small-molecule programs, VENT-03 and…
Celerion Expands UK Phase 1 Trials at Queen’s University Belfast’s iREACH Health Celerion, a global leader in early clinical research, has announced a strategic agreement to relocate its U.K. Phase 1 clinical research operations to the new iREACH Health facility…
Reverb Therapeutics Raises $12M to Advance Amplify•R™ Platform Reverb Therapeutics, a biotechnology company pioneering innovative approaches to harness the natural immune system and cytokine signaling for the treatment of life-threatening diseases, has announced the successful closing of a $12 million…
ICC Arbitral Tribunal Decides in Favor of AOP Health in Arbitration over BESREMi® (Ropeginterferon alfa-2b) A tribunal under the International Chamber of Commerce (ICC) issued a partial final award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its…